Progressive Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Progressive Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: The Synergistic Effects of AIH and FES in Persons With MS [NA]
This clinical trial update covers a study evaluating the synergistic effects of AIH and Functional Electrical Stimulation (FES) in people wi…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis [Phase 1, Phase 2]
Clinical trial update assessing safety and efficacy of melatonin in patients with multiple sclerosis, including primary progressive multiple…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
A completed non-interventional study evaluating ocrelizumab in participants with relapsing-remitting or primary progressive multiple scleros…
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. [Phase 3]
A Phase 3 clinical trial update evaluating the long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis, in…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients [NA]
A University of Michigan–led clinical trial is recruiting to test whether virtual nature walks can alleviate depressive symptoms in people w…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis [Phase 3]
This document describes an ongoing Phase 3 clinical trial evaluating ocrelizumab in participants with progressive multiple sclerosis, with t…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis [Phase 1]
Phase 1 study update on KYV-101, a CD19 CAR T cell therapy, for treatment-refractory Progressive Multiple Sclerosis, with the trial currentl…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Home Based Functional Balance Intervention for Multiple Sclerosis [NA]
A clinical trial is recruiting to evaluate a home-based functional balance intervention for people with multiple sclerosis. The study appear…
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis [Phase 1]
A Phase 1 trial evaluating intrathecal administration of DUOC-01 in adults with Primary Progressive Multiple Sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) [Phase 3]
The Phase 3 PERSEUS trial of the BTK inhibitor tolebrutinib (SAR442168) for primary progressive multiple sclerosis has completed.
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) [Phase 3]
BEAT-MS is a Phase 3 trial comparing best available therapy to autologous hematopoietic stem cell transplantation for multiple sclerosis; it…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care
A prospective cohort study called Clinnova-MS investigates AI and data science applications in health care for various forms of multiple scl…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis [Phase 1]
A Phase 1 clinical trial investigating allogeneic adipose tissue–derived mesenchymal stromal cells for primary progressive multiple sclerosi…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Study of Circadian Focused Light Therapy in Progressive Multiple Sclerosis [Phase 1]
A Phase 1 study evaluating circadian-focused light therapy for progressive multiple sclerosis is currently enrolling by invitation, sponsore…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Senolytics for Secondary Progressive MS [Phase 1]
A Phase 1 clinical trial evaluating senolytic therapies for secondary progressive multiple sclerosis, sponsored by Ohio State University; th…
-
CLINICAL_TRIALS withdrawal · 2025-12-04Clinical Trial Update: Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease
The clinical trial update confirms that the Novartis-sponsored Managed Access Program for patients with secondary progressive multiple scler…
-
CLINICAL_TRIALS trial_result · 2025-12-04Clinical Trial Update: A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis [Phase 3]
A Phase 3 clinical trial evaluating orelabrutinib for primary progressive multiple sclerosis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-11-28Clinical Trial Update: Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
Clinical trial update reporting the completion of a Special Drug-use Surveillance study for Kesimpta (ofatumumab) 20 mg subcutaneous injecti…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) [Phase 1, Phase 2]
Open-label Phase 1/2 clinical trial assessing safety, disease progression and cellular kinetics of YTB323 in participants with non-active pr…
-
CLINICAL_TRIALS research · 2025-10-31Clinical Trial Update: RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis [Phase 1, Phase 2]
Clinical trial update for RESET-MS, a Phase 1/Phase 2 study evaluating CABA-201 in relapsing-remitting and progressive multiple sclerosis, w…
-
CLINICAL_TRIALS research · 2025-10-30Clinical Trial Update: A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS [Phase 2]
This clinical trial update describes a Phase 2 study of remibrutinib using magnetic resonance imaging in relapsing-remitting, secondary prog…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis [NA]
This clinical trial update reports measurements of serum neurofilaments and GFAP in patients with relapsing-remitting and progressive multip…
-
CLINICAL_TRIALS research · 2025-09-12Clinical Trial Update: Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis [Phase 3]
Phase 3 trial update for masitinib in primary progressive or non-active secondary progressive multiple sclerosis, currently ACTIVE_NOT_RECRU…
-
CLINICAL_TRIALS trial_result · 2025-09-11Clinical Trial Update: A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
A real-world study conducted in Russia assessed the impact of siponimod treatment on patients with secondary progressive multiple sclerosis;…
-
CLINICAL_TRIALS research · 2025-09-04Clinical Trial Update: SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis [Phase 1]
Phase 1 clinical trial evaluating the safety of ixazomib targeting plasma cells in relapsing-remitting and progressive multiple sclerosis; c…